Le tislélizumab en combinaison avec la gemcitabine et le cisplatine est indiqué dans le traitement de première intention du carcinome nasopharyngé récidivant ou métastatique, puis, après une durée maximale de six cycles de traitement combiné, en monothérapie.
Heart Pump Accessory Removal: Abbott Removes HeartMate Mobile Power Unit due to Instances of Sudden Power Loss
FDA is alerting health care providers and lab staff of reports of false positives when using certain Micro Capillary Blood Collection tubes with the LeadCare Testing Systems.
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Bridgewater, NJ, Amneal Pharmaceutical LLC, is recalling two lots of Ropivacaine Hydrochloride Injection, USP, 500mg/100mL, Infusion bags to the hospital/user level as the products may contain an inert fiber identified as polypropylene fibers from the IV bag.
80.211.154.110